The ALOX12 Knockout KYSE-30 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the human KYSE-30 esophageal squamous cell carcinoma cell line. This heterogeneous knockout product offers a physiologically relevant loss-of-function model to investigate the cellular roles of ALOX12, which encodes arachidonate 12-lipoxygenase, an enzyme critical in eicosanoid biosynthesis. By ablating target gene expression across a mixed cell pool, researchers can study ALOX12-dependent phenotypes while minimizing clonal selection artifacts, making it suitable for high-content screens and pathway analyses.
The host KYSE-30 cell line was established from a well-differentiated esophageal squamous cell carcinoma tumor resected from a 64-year-old male Japanese patient. As an epithelial cell model, KYSE-30 retains hallmark signalling pathways of ESCC and is extensively utilized in preclinical cancer research, including studies of tumorigenesis, invasion, and therapeutic resistance. Its well-characterized genetic background and reproducible growth properties provide a robust platform for interrogating gene function in the context of upper aerodigestive tract malignancies.
ALOX12 initiates the arachidonic acid metabolic cascade by converting arachidonic acid??released from membrane phospholipids by phospholipase A2??into 12-HPETE, which is subsequently reduced to the bioactive lipid mediator 12-HETE. This reaction requires calcium ions and an iron cofactor. 12-HETE acts via the GPR31 receptor to stimulate downstream signals, including the PI3K/Akt and MAPK pathways, thereby regulating cell proliferation, migration, and survival. ALOX12 activity is positively modulated by upstream inputs such as intracellular calcium, protein kinase A, protein kinase C, and interleukin-4, while its enzymatic output influences transcription factors NF-??B and AP-1, integrin activation, and the generation of reactive oxygen species. Cross-talk with parallel lipoxygenases (e.g., ALOX5) and cyclooxygenase-2 further shapes the cellular eicosanoid profile and inflammatory responses.
Within KYSE-30 cells, ALOX12 is implicated in esophageal cancer progression, contributing to enhanced proliferative capacity, metastatic behavior, and reduced chemosensitivity. Loss-of-function analysis using this polyclonal knockout population permits dissection of how 12-HETE-mediated signalling sustains the malignant phenotype of ESCC. The model is particularly valuable for exploring the intersection of arachidonic acid metabolism and oncogenic signalling, and for testing whether targeting ALOX12 can restore sensitivity to standard-of-care agents like cisplatin. It also enables comparative studies between ALOX12-dependent and -independent modes of tumor cell adaptation.
Experimentally, these polyclonal knockout cells are suited for a range of applications: quantifying 12-HETE production via ELISA following arachidonic acid stimulation; assessing cell proliferation with CCK-8 assays; performing Transwell migration and invasion assays to evaluate metastatic potential; and measuring apoptosis using Annexin V/PI staining. Drug sensitivity profiling can elucidate the role of ALOX12 in chemoresistance, while transcriptomic (RNA-seq) and proteomic (Western blotting/RT-qPCR) analyses can map pathway alterations upon ALOX12 disruption. Additionally, combinatory studies with lipoxygenase inhibitors or siRNAs targeting interacting factors such as PLA2 or GPR31 can further delineate signalling hierarchies. For further information or custom cell engineering services, please contact Ascent Research.
